Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss common myths and misconceptions surrounding antidepressants, antipsychotics, and medications for addiction treatment in congregate care settings.
SARC041 data shows the clinical benefits associated with abemaciclib in the treatment of patients with incredibly rare diseases.
Apalutamide plus androgen deprivation therapy significantly increased the curative success of radical prostatectomy in patients with localized prostate cancer.
APP-led benign hematology consult programs helped community oncology practices significantly reduce time to first appointment while strengthening interdisciplinary collaboration with pharmacists and physicians.
This interview discusses emerging immunotherapy trends at the 2026 ASCO Annual Meeting, including cancer vaccines, cell-based therapies, ADCs, and AI-driven immune profiling tools poised to reshape oncology care.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Jacci Bainbridge, PharmD, FCCP, Professor Vice Chair for Research and Scholarship, Neurology Pharmacy, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking long-term MS therapy, de-escalation, biomarkers and the future of care for MS.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Patricia K. Coyle, MD, a Director at the MS Center at Stony Brook Medicine, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking escalation strategies in relapsing MS.
Proteomic liquid biopsy technology may improve early breast cancer detection, guide targeted therapy selection, and support longitudinal treatment monitoring in oncology care.
Pharmacists play a big role in biomarker testing, patient selection, and counseling on immune checkpoint inhibitor therapy in endometrial cancer.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Donald Langan, PharmD, MD, a Multiple Sclerosis and Clinical Neuroimmunology Fellow at Columbia University, presenting on the evolution of GLP-1 receptor agonists, discussed the future of GLP-1 therapies and the expansion of the pharmacist's role.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what the pharmacist's role in MS supplement safety.
Pharmacists unpack easier access to PCSK9 inhibitors and inclisiran—smart prior auth, Medicare Part B nuances, and foundation help that cuts costs.
Paste the article text (or an excerpt), and I’ll generate a 150-character, 24-word max SEO meta description in present tense.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what works and what doesn't in MS supplements.
Researchers discuss how GLP-1 receptor agonists may be associated with improved survival outcomes in breast cancer and what clinicians should consider as use of these therapies continues to grow.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic, presenting on management of High-risk multiple sclerosis patients, discussed what the pharmacist's role is in managing high-risk MS patients.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic presenting on management of High-risk multiple sclerosis patients, discussed safety, treatment, and emerging strategies.
Joe DePinto of McKesson outlines the workflow barriers slowing CGT migration to community oncology, the reimbursement reforms needed to scale access, and the pharmacist’s pivotal role in making it all work.
Joe DePinto of McKesson discusses how payers, providers, and employers diverge on CGT reimbursement—and why outcomes-based payment models may hold the key to broader patient access.
Adding immune checkpoint inhibitors to carboplatin and paclitaxel has become the new frontline standard for advanced or recurrent endometrial cancer.
This week's episode covers the White House's expansion of the TrumpRx.gov platform, the pharmacist's critical role in closing adult hepatitis B vaccination gaps, and new FDA approvals in immunology, oncology, and cardiovascular care.
Natalie Bellini, DNP, FNP-BC, BC-ADM, breaks down how updated ADA guidelines have broadened eligibility for continuous glucose monitors, automated insulin delivery systems, and continuous ketone monitoring.
Discover how pharmacists drive biomarker testing, speed therapy approvals, and guide safer immunotherapy decisions in endometrial
Pharmacists boost biomarker testing access and education, streamline therapy approvals, and guide safe immunotherapy dosing in endometrial cancer through proactive IRAE monitoring.
On World Schizophrenia Day, a psychiatric pharmacist details how EHR fragmentation drives medication errors in schizophrenia care, and why provider recognition is essential to fixing it.
Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists should approach continuous glucose monitoring (CGM) report review and explains why individualized patient education is key.
GLP-1 receptor agonists, molecular profiling, and biomarker-driven treatment strategies may help improve outcomes and personalize care for patients at risk for or diagnosed with endometrial cancer.
Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, explains how pharmacists can better leverage underutilized continuous glucose monitoring (CGM) app features and address the education gaps that prevent patients from achieving long-term CGM persistence.
Pharmacists can use immunization registry data, collaborative practice agreements, and evidence-based vaccine advocacy to close adult hepatitis B care gaps.
